Valuation: Proteomics International Laboratories Ltd

Market Cap 19M 13.36M 11.6M 10.86M 9.93M 18.75M 1.27B 127M 49.85M 636M 50.17M 49.08M 2.12B P/E 2024
-17.4x
P/E 2025 -5.38x
Enterprise Value 8.24M 5.79M 5.03M 4.71M 4.31M 8.13M 552M 55.08M 21.62M 276M 21.76M 21.28M 918M EV / Sales 2024
33.2x
EV / Sales 2025 12.8x
Free-Float
74.56%
Yield 2024 *
-
Yield 2025 -
1 year 0.26
Extreme 0.26
0.26
3 years 0.26
Extreme 0.26
0.31
5 years 0.26
Extreme 0.26
0.31
10 years 0.26
Extreme 0.26
0.31
Manager TitleAgeSince
Chief Executive Officer - 2026-01-18
Director of Finance/CFO - 2026-04-16
Director of Finance/CFO - 2021-07-11
Director TitleAgeSince
Director/Board Member - 2017-11-21
Chairman 56 -
Director/Board Member - 2024-11-07
Change 5-day change 1-year change 3-year change Capi.($)
-16.13%-.--% - - 18.65M
-3.25%+12.81%+52.96%+88.86% 64.9B
+0.69%-2.81%+25.84%+68.41% 54.05B
-1.07%-1.89%-17.90%-14.36% 23.16B
+33.86%+28.54%+18.76%+502.77% 21.46B
+1.87%+5.08%+29.88%-7.94% 21.25B
-0.79%+0.54%+31.17%-25.84% 17.94B
-3.37%+19.44%+211.98%+369.13% 17.03B
+3.29%+2.09%+17.32%+586.49% 14.99B
-7.94%-5.66%+39.35%+157.52% 14.25B
Average +0.72%+3.37%+45.49%+191.67% 27.67B
Weighted average by Cap. +1.74%+3.64%+41.95%+147.01%

Financials

2024 2025
Net sales 3.28M 2.3M 2M 1.87M 1.71M 3.23M 220M 21.91M 8.6M 110M 8.65M 8.46M 365M 3.31M 2.33M 2.02M 1.89M 1.73M 3.27M 222M 22.15M 8.69M 111M 8.75M 8.56M 369M
Net income -6.38M -4.49M -3.89M -3.64M -3.33M -6.29M -427M -42.64M -16.73M -213M -16.84M -16.47M -711M -8.11M -5.71M -4.95M -4.64M -4.24M -8.01M -544M -54.27M -21.3M -272M -21.43M -20.97M -904M
Net Debt -6.32M -4.45M -3.86M -3.61M -3.31M -6.24M -424M -42.29M -16.6M -212M -16.7M -16.34M -705M -10.76M -7.57M -6.57M -6.15M -5.63M -10.62M -721M -71.95M -28.24M -360M -28.42M -27.8M -1.2B
Logo Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd is an Australia-based medical technology company. The Company is engaged in predictive diagnostics and bioanalytical services. It specializes in the area of proteomics, the industrial scale study of the structure and function of proteins. It focuses on developing and commercializing diagnostic tests for chronic diseases. Its principal activities fall into three key areas: commercialization of PromarkerD, the predictive test for diabetic kidney disease (DKD) and future kidney function decline in patients with type 2 diabetes; precision diagnostic tests in development: the Promarker pipeline, and specialist accredited analytical services on a commercial basis. Its Promarker pipeline and analytical services include PromarkerEndo, PromarkerEso and OxiDx technology. PromarkerEndo is a prototype diagnostic test for endometriosis identifying up to 90% of patients with the disease. PromarkerEso is a prototype diagnostic test for esophageal cancer.
Employees
-

Annual profits - Rate of surprise